| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| Other Sizes |
| Targets |
As a fluorescent probe rather than a therapeutic agent, FITC-Ureidopropionic acid does not exert biological activity by binding to specific pharmacological targets. The probe is designed to utilize ureidopropionic acid as a carrier molecule. Ureidopropionic acid is an endogenous metabolite involved in pyrimidine and amino acid metabolism, serving as an intermediate in the uracil degradation pathway where it is converted from dihydrouracil by dihydropyrimidinase and subsequently to β-alanine by β-ureidopropionase . Thus, the probe can theoretically be used to study the biodistribution and metabolic fate of this metabolite.
|
|---|---|
| ln Vitro |
FITC-Ureidopropionic acid is not designed to exert direct pharmacological activity (e.g., enzyme inhibition or receptor activation). Its primary in vitro application is as a fluorescent labeling reagent for biomolecules and cells. The FITC moiety provides bright green fluorescence with good photostability when excited at 490 nm and detected at 520 nm . The probe's activity is defined by its fluorescence signal intensity, which can be quantified via fluorescence spectrophotometry, flow cytometry, or fluorescence microscopy . The small molecular size of the probe facilitates cellular uptake, enabling intracellular tracking applications .
|
| ln Vivo |
FITC-Ureidopropionic acid lacks traditional in vivo pharmacodynamic activity as it is not a therapeutic compound. However, it serves as a valuable tool for in vivo tracking studies. The fluorescent label allows visualization of the probe's distribution, accumulation, and potential metabolic transformation in living organisms. The ureidopropionic acid component can theoretically direct the probe to tissues or cells involved in pyrimidine metabolism . No specific therapeutic efficacy data is available, as the probe is exclusively for research applications.
|
| Enzyme Assay |
As a fluorescent probe, FITC-Ureidopropionic acid is not typically used in standard enzyme inhibition or receptor binding assays. However, fluorescence intensity detection protocols are well-established for this compound. A representative fluorescence measurement protocol using a fluorescence spectrophotometer is as follows: Prepare FITC-Ureidopropionic acid solutions at known concentrations in an appropriate buffer (e.g., PBS, pH 7.4). Set the excitation wavelength to approximately 495 nm and scan the emission spectrum from 500-600 nm to identify the maximum emission wavelength (typically ~520 nm). Then, measure fluorescence intensity at the optimized excitation/emission pair and construct a standard curve of fluorescence intensity versus concentration. Unknown samples can be quantified by interpolation from this standard curve .
|
| Cell Assay |
FITC-Ureidopropionic acid is widely used in cell-based fluorescence assays for tracking and imaging applications. A standard cell labeling protocol: Culture target cells (e.g., hepatocytes or cancer cell lines) in appropriate medium to desired confluence. Incubate cells with FITC-Ureidopropionic acid (concentration optimization required, typically starting at 1-10 μM) in culture medium for 30-60 minutes at 37°C in a 5% CO₂ incubator. Wash cells thoroughly with PBS to remove unbound probe. Fluorescence signals can then be analyzed using fluorescence microscopy for subcellular localization studies, flow cytometry for quantitative analysis of cellular uptake, or microplate fluorescence readers for high-throughput quantification . For cell tracking experiments, the labeled cells can be monitored over time to assess probe retention and distribution .
|
| Animal Protocol |
In vivo animal studies using FITC-Ureidopropionic acid are primarily for biodistribution and metabolic tracking purposes. While specific published protocols are limited, a general approach is described: Administer FITC-Ureidopropionic acid to research animals (e.g., mice or rats) via appropriate routes (intravenous, intraperitoneal, or oral depending on study objectives). At predetermined time points post-administration, collect tissues of interest (liver, kidney, blood, brain, etc.) and prepare homogenates or frozen sections. Fluorescence signals can be visualized using in vivo imaging systems (IVIS) for whole-body distribution, or ex vivo via fluorescence microscopy of tissue sections. Quantitative analysis of probe concentration in tissues can be performed by extracting the fluorescent compound and measuring fluorescence intensity against a standard curve .
|
| ADME/Pharmacokinetics |
Specific pharmacokinetic data for FITC-Ureidopropionic acid (such as half-life, volume of distribution, clearance, bioavailability) is not available in standard literature. As a research-use fluorescent probe, detailed PK profiling is typically not performed for this type of compound. However, the physicochemical properties of the probe can be inferred from its solubility characteristics: the compound is soluble in DMSO and exhibits good water solubility, which may facilitate absorption and distribution . The molecular weight is 563.58 g/mol . Stability data indicates that the probe requires protection from light during storage and handling; powder form is stable at -20°C for up to 3 years, and solutions are stable for 6 months at -80°C or 1 month at -20°C . These properties suggest that in vivo applications would require protection from photobleaching and consideration of the probe's metabolic stability.
|
| Toxicity/Toxicokinetics |
According to available product information, FITC-Ureidopropionic acid is for research use only and not for human diagnostic or therapeutic purposes . Specific toxicological data (e.g., LD50, cytotoxicity IC50) is not provided in standard product specifications. General handling precautions include protection from light during transportation and storage, as light exposure may degrade the fluorescent compound . The compound is typically stored as a light yellow to yellow solid powder at -20°C for long-term stability . Users should follow standard laboratory safety practices, including wearing appropriate personal protective equipment, avoiding inhalation and skin contact, and disposing of waste according to institutional regulations. As a fluorescein derivative, the compound generally exhibits low intrinsic toxicity, but individual researchers should conduct appropriate cytotoxicity assays for their specific cell types and experimental conditions.
|
| Molecular Formula |
C27H25N5O7S
|
|---|---|
| Molecular Weight |
563.58
|
| Related CAS # |
Ureidopropionic acid;462-88-4
|
| Appearance |
Light yellow to yellow solid powder
|
| Synonyms |
FITC-3-Ureidopropionate; FITC-Ureidopropionic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.7744 mL | 8.8719 mL | 17.7437 mL | |
| 5 mM | 0.3549 mL | 1.7744 mL | 3.5487 mL | |
| 10 mM | 0.1774 mL | 0.8872 mL | 1.7744 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
